Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the causes of severe
hyperbilirubinemia, prolonged jaundice, and bilirubin-induced encephalopathy in neonates …

Aim This study aimed to investigate the effect of adding ursodeoxycholic acid (UDCA) to
phototherapy in neonates with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency …

Introduction and aims Phototherapy is the most common treatment modality of neonatal
hyperbilirubinemia. We aimed to evaluate the therapeutic effect of oral Ursodeoxycholic Acid …

Objectives Indirect hyperbilirubinemia during neonatal period is a common problem, and
most preterm and more than half of the term neonates find this problem. Ursodeoxycholic …

Objective The aim was to evaluate the role of ursodeoxycholic acid (UDCA) on neonatal
indirect hyperbilirubinemia treated with phototherapy. Background Hyperbilirubinemia is a …

ABSTRACT Background: Ursodeoxycholic Acid (UDCA) is a bile acid widely used in the
treatment of cholestatic liver disorders. Few studies have been conducted using UDCA in …

Objective: To investigate the effect of USDA in the treatment of indirect hyperbilirubinemia of
neonates. Study design: This randomized clinical trial was conducted on neonates with …

Objectives: This study aimed to compare ursodeoxycholic acid and phototherapy versus
phototherapy in lowering the level of bilirubin in neonates who was admitted due to …

Background Neonatal hyperbilirubinemia is observed in most newborns, and 5–15% of
neonates require phototherapy. Phototherapy is effective but often prolongs hospitalization …

Background Hyperbilirubinemia is a global problem in neonates. Classic management for
indirect neonatal hyperbilirubinemia includes phototherapy and exchange transfusion …